uniQureQURE
QURE
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 209
0
Funds holding %
of 7,430 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
457% more call options, than puts
Call options by funds: $64.5M | Put options by funds: $11.6M
37% more capital invested
Capital invested by funds: $532M [Q1] → $728M (+$196M) [Q2]
10% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 29
2.87% more ownership
Funds ownership: 92.46% [Q1] → 95.33% (+2.87%) [Q2]
0% more funds holding
Funds holding: 140 [Q1] → 140 (+0) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 46
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
123%
upside
Avg. target
$53
234%
upside
High target
$70
346%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin | 123%upside $35 | Buy Maintained | 29 Jul 2025 |
HC Wainwright & Co. Patrick Trucchio | 346%upside $70 | Buy Reiterated | 29 May 2025 |
Financial journalist opinion
Based on 6 articles about QURE published over the past 30 days
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet
The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
Benzinga
3 weeks ago
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Prasad resigned.
Neutral
Seeking Alpha
3 weeks ago
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
uniQure N.V. (NASDAQ:QURE ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Sushila Hernandez - Van Lanschot Kempen Luca Issi - RBC Capital Markets, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Samantha Corwin - William Blair & Company L.L.C.
Neutral
The Motley Fool
4 weeks ago
uniQure Narrows Loss in Fiscal Q2
uniQure Narrows Loss in Fiscal Q2
Negative
Zacks Investment Research
4 weeks ago
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure (QURE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $1.16 per share a year ago.
Neutral
GlobeNewsWire
4 weeks ago
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;
Neutral
GlobeNewsWire
1 month ago
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET
Neutral
GlobeNewsWire
2 months ago
uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.
Neutral
GlobeNewsWire
2 months ago
uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease
~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.
Positive
Seeking Alpha
2 months ago
uniQure's AMT-130 Gene Therapy Warrants An Upgrade
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.
Charts implemented using Lightweight Charts™